设计,合成,反扩散效应和含的各种碳环的比古安化衍生物的机械细节
Yijun Xie1, Qingtong Zhang1, Di Xiao1
1Department of Oncology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Engineering Research Center of Reproduction and Translational Medicine of Hunan Province, Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research of Ministry of Education, Key Laboratory of Protein Chemistry and Developmental Biology of Fish of Ministry of Education, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, Hunan, China.
Medicinal chemistry (Shariqah (United Arab Emirates))
|December 15, 2025
概括
合成了具有不同碳环的新型比古安化衍生物,并对抗癌活性进行了测试. 含有环素的3,4-二二比古安化物通过抑制EGFR通路,显示出最强的抗瘤作用,特别是对T24细胞.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 比古安化物衍生物显示出作为抗瘤剂的前景.
- 不同碳环结构对比古安化物反扩散活动的影响仍未得到充分研究.
研究的目的:
- 合成含有的新型比古安化物化合物,具有多种碳环.
- 评估它们的抗癌活动和抗增殖机制.
- 调查这些大类的结构-活性关系.
主要方法:
- 合成了9种新型的瓜尼丁衍生物,其中含有三甲基或3,4-二二基和不同循环氨基循环碳.
- 使用MTT和克隆基因测试评估的抗增殖活性.
- 通过西式涂抹探索作用机制,以分析蛋白质表达水平.
主要成果:
- T24细胞对合成的比古安化衍生物表现出最高的敏感性.
- 化合物4b在 HepG2, Ovcar3 和 T24 细胞系中表现出最强的生长抑制.
- 西部涂抹显示,化合物4b抑制EGFR信号通路,有助于瘤生长抑制.
结论:
- 含有环素的3,4-二二比古安化类型 (1a-5a和1b-4b) 显示出作为抗癌药物候选者的巨大潜力.
- 在测试的衍生品中,3,4-二二乙烯比古安化与循环基部分表现出优越的抗瘤活性.
- 这些发现为开发基于比瓜尼德的增强型抗癌疗法提供了新的方向.
关键词:
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 5 5 5 5 5 6 6 7 7 7 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 including including including including including including including including including including including4-二二烯基的使用.巨人之类的东西.欧洲农业基金会 (EGFR) 是一个.这是一种抗癌药物.循环活化. 循环活化.瘤的生长 瘤的生长更多相关视频
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
01:13Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene
7.3K
Bromination and chlorination of aromatic rings by electrophilic aromatic substitution reactions are easily achieved, but fluorination and iodination are difficult to achieve. Fluorine is so reactive that its reaction with benzene is difficult to control, resulting in poor yields of monofluoroaromatic products. To address this, Selectfluor reagent is used as a fluorine source in which a fluorine atom is bonded to a positively charged nitrogen.
7.3K
01:17Oral Hypoglycemic Agents: Sulfonylureas
724
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
724
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
1.5K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.5K
01:06Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565